Discovery - University of Dundee - Online Publications

Library & Learning Centre

Langwirksame medikamente zur behandlung der hyperkinetischen störungen.

Langwirksame medikamente zur behandlung der hyperkinetischen störungen.: Eine systematische übersicht und europäische behandlungsleitlinien.Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate

Research output: Contribution to journalArticle

View graph of relations


  • Tobias Banaschewski (Lead / Corresponding author)
  • D. Coghill
  • Paramala Santosh
  • Aleassandro Zuddas
  • Philip Asherson
  • Jan Buitelaar
  • Marina Danckaerts
  • Manfred Döpfner
  • Stephen V. Faraone
  • Aribert Rothenberger
  • Joseph Sergeant
  • Hans-Christoph Steinhausen
  • Edmund J.S. Sonuga-Barke
  • Eric Taylor

Research units


Translated title of the contributionLong-acting medications for the treatment of hyperkinetic disorders : A systematic review and European treatment guideline. Part 2: A quantitative evaluation of long-acting medications
Original languageGerman
Pages (from-to)97-107
Number of pages11
JournalZeitschrift fur Kinder-und Jugendpsychiatrie und Psychotherapie
Issue number2
StatePublished - 1 Mar 2008


A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder. Based on this analysis detailed recommendations about the use of these drugs in practice have been developed: (1) Long-acting preparations should be licensed and used; (2) They should not completely replace short-acting drugs (which will be the initial treatment for many children in view of cost and the greater flexibility of dosing). Individual clinical choices are necessary. (3) Both ATX and extended-release stimulants should be available. In addition, detailed recommendations will be made with regard to the criteria to be applied in choosing a preparation for the individual patient. © 2008 by Verlag Hans Huber, Hogrefe AG.



Library & Learning Centre

Contact | Accessibility | Policy